Technical Analysis for SNSS - Sunesis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.14 -2.56% -0.03
SNSS closed down 2.56 percent on Monday, May 20, 2019, on 67 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical SNSS trend table...

Date Alert Name Type % Chg
Golden Cross Bullish 0.00%
Hammer Candlestick Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Down 3 Days in a Row Weakness -2.56%
Lower Bollinger Band Touch Weakness -2.56%

Older signals for SNSS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company's principal product includes Vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It is conducting various clinical trials of Vosaroxin, including a Phase III clinical trial, known as the VALOR trial in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and a Phase II/III trial known as the LI-1 trial in patients older than 60 years with AML or high-risk myelodysplastic syndrome. In addition, the company has completed the Phase II portion of a Phase Ib/II trial of Vosaroxin in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and Phase II trial in previously untreated patients with 60 years of age or older with AML or REVEAL-1 trial, which explored three dosing schedules of vosaroxin. It has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and commercialization of Vosaroxin; a collaboration agreement with Millennium for the development of pan-Raf kinase inhibitor and one additional undisclosed kinase inhibitor program in oncology; and a collaboration agreement with Biogen Idec, Inc. to discover, develop, and commercialize small molecule inhibitors of a preclinical kinase inhibitor program in immunology. The company formerly known as, Mosaic Pharmaceuticals, Inc., was founded in 1998 and is headquartered in South San Francisco, California.
Biopharmaceutical Drugs Chemical Compounds Organic Compounds Acute Myeloid Leukemia Myelodysplastic Syndrome Orphan Drugs Treatment Of Acute Myeloid Leukemia Lactams High Risk Myelodysplastic Syndrome
Is SNSS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.87
52 Week Low 0.2
Average Volume 925,498
200-Day Moving Average 1.2317
50-Day Moving Average 1.2471
20-Day Moving Average 1.3155
10-Day Moving Average 1.246
Average True Range 0.1454
ADX 21.34
+DI 15.0445
-DI 22.0135
Chandelier Exit (Long, 3 ATRs ) 1.1438
Chandelier Exit (Short, 3 ATRs ) 1.4562
Upper Bollinger Band 1.5176
Lower Bollinger Band 1.1134
Percent B (%b) 0.07
BandWidth 30.72596
MACD Line -0.026
MACD Signal Line 0.0061
MACD Histogram -0.0321
Fundamentals Value
Market Cap 26.8 Million
Num Shares 23.5 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -0.60
Price-to-Sales 24.54
Price-to-Book 0.00
PEG Ratio -0.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.25
Resistance 3 (R3) 1.24 1.20 1.23
Resistance 2 (R2) 1.20 1.17 1.20 1.22
Resistance 1 (R1) 1.17 1.16 1.15 1.18 1.22
Pivot Point 1.13 1.13 1.12 1.13 1.13
Support 1 (S1) 1.10 1.10 1.08 1.11 1.06
Support 2 (S2) 1.06 1.09 1.06 1.06
Support 3 (S3) 1.03 1.06 1.05
Support 4 (S4) 1.04